Recognizing that our traditional models to pandemic preparedness have failed to imagine the risk and broad societal impact of biological threats, McMaster University sought support to establish a new way forward.
A global health consortium required support in attracting greater industry investment into the traditionally underfunded area of Strep A vaccine development.
In the face of constrained R&D budgets, a top-5 pharmaceutical company needed support to develop a transformative, corporate-wide strategy to assess and secure external funding.
Facing the need to de-risk the development of new vaccines, a top-10 biopharma company required help articulating the strategic vision and business case for a translational research public-private partnership.
The Pox-Protein Public-Private Partnership (P5) is tackling an enduring and daunting challenge: developing the world’s first HIV vaccine and ensuring it achieves maximum public health impact.
The International Vaccine Institute in South Korea and the Saudi Ministry of Health required strategic and facilitation support to advance a collaborative approach to MERS-CoV vaccine development.
A global pharmaceutical company wanted to identify diagnostic technologies that would support the clinical development and commercial performance of agents targeting two infectious diseases and represent potential partnership opportunities.
Shift Health was engaged by a newly formed government-funded agency to develop a foreign direct investment (FDI) attraction strategy for the Toronto Region’s healthcare and life sciences cluster.